SEC Form 4 · accession 0001214659-18-005702
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — President & CEO · Director
Period of report
Aug 23, 2018
Accepted (ET)
Aug 24, 2018 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 23, 2018 | M | 51,810 | $8.50 | A | 102,742 | D | |
| Common StockF2 | Aug 23, 2018 | S | 17,434 | $56.8848 | D | 85,308 | D | |
| Common StockF3 | Aug 23, 2018 | S | 32,514 | $57.862 | D | 52,794 | D | |
| Common StockF4 | Aug 23, 2018 | S | 1,862 | $58.3962 | D | 50,932 | D | |
| Common Stock | Aug 24, 2018 | M | 11,486 | $17.41 | A | 62,418 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF5 | $8.50 | Aug 23, 2018 | M | 51,810 | D | — | Jul 16, 2020 | Common Stock | 51,810 | 103,620 | D |
| Common StockF6 | $17.41 | Aug 24, 2018 | M | 11,486 | D | — | May 20, 2024 | Common Stock | 11,486 | 138,514 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $56.30 to $57.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $57.30 to $58.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $58.30 to $58.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F520% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.
- F61/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.